Company intelligence / Profile preview
ERC Belgium
Isnes, Namur, Belgiumerc-biotech.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
ERC is a clinical-stage biopharmaceutical company focused on developing personalized cell-based immunotherapies for brain cancer and other solid tumors. Its lead product, Gliovac (ERC1671), is a first-in-class immunotherapy that combines autologous and allogeneic tumor cells to trigger a comprehensive immune response against glioblastoma multiforme. The company's approach is designed to overcome the high heterogeneity of tumors by using a broad spectrum of tumor-associated antigens. ERC is headquartered in Belgium and maintains active clinical development programs in both Europe and the United States.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of California, IrvineMedical University of Vienna
Beyond the preview
Go deeper on ERC Belgium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERC Belgium.